Every 10-Q that NuSkin Enterprises, Inc. (NUS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow NUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NUS filings page.
Nu Skin Enterprises reported significantly weaker results for the quarter and six months ended June 30, 2026. Revenue fell 17.1% to $320.1 million in the quarter and 14.6% to $640.7 million year-to-date, driven by broad-based declines across all Nu Skin geographies and both Rhyz segments, as macroeconomic pressures reduced consumer spending and customer acquisition. Customers declined 14%, Paid Affiliates 8%, and Sales Leaders 9% year over year.
Profitability deteriorated sharply. The company recorded an operating loss of $59.3 million for the quarter and a net loss of $249.8 million, versus net income of $21.1 million a year earlier. For the first half, net loss was $248.0 million, compared to $128.6 million in 2025. Results were heavily impacted by a $78.9 million goodwill impairment in the Manufacturing segment and a $167.5 million valuation allowance against U.S. deferred tax assets, producing an effective tax rate of (295.4)% for the quarter. Diluted EPS swung to $(5.14) for the quarter and $(5.12) year-to-date, versus $0.43 and $2.59, respectively.
Despite the downturn, gross margin remained high at 68.2% for the quarter. Operating cash flow was positive but modest at $6.7 million for the first half, while cash and cash equivalents decreased to $189.6 million from $238.6 million at year-end 2025. The company refinanced its credit facilities with a new $175 million term loan and $75 million revolver and reported compliance with leverage and interest coverage covenants. Nu Skin continued paying quarterly dividends of $0.06 per share and repurchased 0.5 million shares for $5.0 million in the first half.
Nu Skin Enterprises reported weaker results for the first quarter of 2026. Revenue fell 12.0% to $320.6 million from $364.5 million, as macroeconomic pressures and its ongoing business transformation reduced consumer spending and customer acquisition. Customers declined 14%, Paid Affiliates 8% and Sales Leaders 13% year over year across its core Nu Skin business.
Net income dropped to $1.8 million, or $0.04 per diluted share, compared with $107.5 million, or $2.14 per diluted share, a year earlier, when results benefited from a large gain on the sale of the Mavely business. The 2026 quarter also included $5.9 million of charges tied to winding down the BeautyBio business.
Gross margin slipped to 66.9%, while selling expenses rose to 34.3% of revenue as the company supported changes to its sales performance plan and the Prysm iO wellness platform rollout. Nu Skin ended the quarter with $200.4 million in cash and current investments, $225 million of total debt under a new credit agreement, and modestly negative operating cash flow.
Nu Skin Enterprises (NUS) reported Q3 2025 results. Revenue was $364.2 million, down 15% year over year as macro headwinds weighed on demand and field activity. Operating income rose to $21.6 million from $18.2 million. Net income was $17.1 million ($0.34 diluted EPS) versus $8.3 million a year ago.
For the first nine months of 2025, revenue was $1,114.8 million, down 13% year over year. Net income reached $145.7 million, reflecting a $176.2 million gain on the January sale of the Mavely business. Core costs were lower: selling and G&A declined versus last year, and restructuring charges were significantly lower than 2024.
The balance sheet strengthened. Cash and cash equivalents were $251.8 million versus $186.9 million at year-end 2024. Long-term debt fell to $209.0 million from $363.6 million, aided by $220.0 million of debt payments year-to-date, including a $115.0 million term-loan paydown funded by sale proceeds. The company paid quarterly dividends of $0.06 per share and repurchased $10.0 million of stock year to date, with $152.4 million remaining under the authorization. As of November 1, 2025, 48,750,076 Class A shares were outstanding.